Amyloidosis Research Consortium (ARC)
Kaye Gooch serves as the Director of Community Programs at the Amyloidosis Research Consortium (ARC) since September 2024. Previously, Kaye held multiple leadership roles at the National MS Society from 1994 to 2024, including Associate Vice President of Stakeholder Engagement & Strategy, where responsibilities included leading a nationwide team to improve care access for individuals with Multiple Sclerosis and overseeing a network of over 330 MS specialists. As Executive Vice President of Programs, Services & Volunteers, Kaye managed a budget of 650K and directed key initiatives in North and South Carolina, focusing on education and community partnerships. Kaye also held the position of Chapter Services Director, where efforts led to the development of comprehensive programs in eastern North Carolina. Kaye's contributions included spearheading a diversity outreach initiative that resulted in the first national conference for African Americans living with MS. Kaye holds a Master's degree in Social Work from the University of North Carolina at Chapel Hill and a Bachelor's degree in Social Work from the University of North Carolina at Greensboro.
This person is not in any teams
This person is not in any offices
Amyloidosis Research Consortium (ARC)
The Amyloidosis Research Consortium (ARC) addresses critical needs in clinical trials and related research for the underserved group of systemic amyloid diseases. We have created a collaborative research model to bring together experts in the field to address the challenges that exist in developing diagnostic tools and to carrying out innovative clinical trials. Stay up to date with the latest news and research from ARC's newsletter: http://www.arci.org/newsletter-sign-up ARC is committed to building collaborative relationships between patients, academia, industry, foundations, federal funders, and regulators to advance the best research and speed new therapies to market. ARC is focused on increasing the amount of research and building a prioritized portfolio of translational research and clinical research. The work of the Amyloidosis Research Consortium has been made possible through the generous support of our donors. With continued funding of our strategic and vital research programs, you are investing in a promising future for amyloidosis patients. You can donate here: www.arci.org/donate